Julie Hylton serves as the Principal Talent Acquisition Business Partner for the Americas at Novartis, where she plays a pivotal role in shaping the future of the company’s workforce. With a focus on the Innovative Medicines US Organization, Julie leads talent acquisition efforts across critical...
Julie Hylton serves as the Principal Talent Acquisition Business Partner for the Americas at Novartis, where she plays a pivotal role in shaping the future of the company’s workforce. With a focus on the Innovative Medicines US Organization, Julie leads talent acquisition efforts across critical areas such as Research and Development, Medical Affairs, and various specialized roles including Medical Science Liaisons and Health Economics and Outcomes Research (HEOR). Her extensive expertise in executive search and international marketing allows her to identify and attract top-tier talent who are not only skilled but also align with Novartis's mission to reimagine medicine and address significant medical needs.
Julie is currently spearheading key projects aimed at enhancing employer branding and streamlining the onboarding process, ensuring that new hires are seamlessly integrated into Novartis's dynamic culture. By leveraging innovative digital recruiting strategies and advanced screening techniques, she is committed to building a diverse and inclusive workforce that reflects the communities Novartis serves. Her proficiency in personnel management and deferred compensation strategies further enhances her ability to attract and retain high-caliber professionals in a competitive landscape.
In addition to her operational responsibilities, Julie is a thought leader in talent acquisition trends within the pharmaceutical industry. She actively contributes to discussions on best practices in recruitment, emphasizing the importance of aligning talent strategies with organizational goals. Her passion for fostering a collaborative environment not only supports Novartis's growth but also empowers individuals to thrive in their careers, ultimately contributing to the company's mission of improving and extending people's lives through innovative therapies.
